VA Palo Alto Health Care System .
Welcome,         Profile    Billing    Logout  
 6 Trials 
10 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Costello, Brian
NCT05803941: Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

Recruiting
4
700
Europe, Canada, US, RoW
AAA617, lutetium (177Lu) vipivotide tetraxetan, [177Lu]Lu-PSMA-617, 177Lu-PSMA-617
Novartis Pharmaceuticals
Prostate Cancer
07/33
07/33
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT01767636: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Active, not recruiting
2
38
US
Pazopanib Hydrochloride, GW786034B, Votrient
Mayo Clinic, National Cancer Institute (NCI)
Carcinoma of the Collecting Ducts of Bellini, Chromophobe Renal Cell Carcinoma, Kidney Medullary Carcinoma, Kidney Oncocytoma, Metastatic Renal Cell Cancer, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage IV Renal Cell Cancer
02/19
11/24
NCT02876068: Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies

Active, not recruiting
1
19
US
Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, ARRY-142886, AZD6244, MEK Inhibitor AZD6244
Mayo Clinic, National Cancer Institute (NCI)
Solid Neoplasm, Stage IV Skin Melanoma
06/16
 
NCT01364051: Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies

Active, not recruiting
1
19
US
Cediranib, AZ-D2171, AZD 2171, AZD2171, Cediranib Maleate, AZD2171 Maleate, Recentin, Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib, ARRY-142886, AZD 6244, AZD-6244, AZD6244, MEK Inhibitor AZD6244, Selumetinib Sulfate, AZD-6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulfate, AZD6244 Hydrogen Sulphate, Koselugo, Selumetinib Sulphate
National Cancer Institute (NCI)
Metastatic Melanoma, Refractory Malignant Solid Neoplasm, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Malignant Solid Neoplasm
06/19
03/25
NCT02143401: Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Completed
1
29
US
Laboratory Biomarker Analysis, Navitoclax, A-855071.0, ABT-263, BcI-2 Family Protein Inhibitor ABT-263, Pharmacological Study, Sorafenib, BA4 43 9006, BAY 43 9006, BAY 43-9006, BAY 439006, BAY-43-9006, Bay-439006, BAY439006, Sorafenib Tosylate, BAY 43-9006 Tosylate, BAY 54 9085, BAY 54-9085, BAY 549085, BAY-54-9085, BAY549085, Nexavar, sorafenib
National Cancer Institute (NCI)
Cirrhosis, Hepatitis B Infection, Hepatitis C Infection, Metastatic Malignant Solid Neoplasm, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Refractory Malignant Neoplasm, Stage IV Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
11/22
03/24
ODYSSEY RCC, NCT04919122: Outcomes Database to prospectivelY aSSEss the Changing TherapY Landscape in Renal Cell Carcinoma

Recruiting
N/A
800
US
Duke University, Duke Clinical Research Institute, Bristol-Myers Squibb, Exelixis, Merck Sharp & Dohme LLC, Pfizer
Metastatic Renal Cell Carcinoma
07/26
07/26
Vasanawala, Minal
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT04726215: Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Recruiting
2
50
US
[18F]F AraG
CellSight Technologies, Inc.
Non Small Cell Lung Cancer
10/24
10/24
NCT05066776: Liquid Biopsy With PET/CT Versus PET/CT Alone in Diagnosis of Small Lung Nodules

Terminated
N/A
31
US
Palo Alto Veterans Institute for Research
Lung Cancer, Solitary Pulmonary Nodule, Multiple Pulmonary Nodules
02/23
02/23

Download Options